First-in-Human (FIH) Trial of GEN3009 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

AGE: 18 years and older
GENDER: All
TYPE: Drug Study
HEALTHY PARTICIPANTS: No
CONDITION: B-cell Non-Hodgkin Lymphoma

University Hospitals Seidman Cancer Center offers a phase I/IIa clinical trial B-Cell Non-Hodgkin Lymphoma for patients who previously received treatment, the disease is worsening or the disease has come back, or currently do not have any treatment options. This trial is a first-in-human trial to characterize the safety, tolerability, pharmacokinetic and pharmacodynamics characteristics of a DuoHexabody®-CD37.

Who Can Participate

Patients 18 years of age or older who have histologically or cytologically confirmed relapsed and/or refractory B-cell Non-Hodgkin’s Lymphoma and do not have any available standard therapy or are not a candidate for available standard therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN3009 may be beneficial may be eligible for this study.

Learn More About This Research Study

For more information, please contact the study coordinator, Regina Esposito, by filling out the form below or by phone at 216-286-3867.

To learn more about this study, please fill out the form below to request more information.
XXX-XXX-XXXX

Study ID